Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

By H. Vasen, I. Blanco, K. Aktán-Collán, J. P. Gopie, Á. Alonso, S. Aretz, I. Bernstein, L. Bertario, J. Burn, G. Capellá and 26 more. Gut, 2013

727 citations recorded by the source corpus.

Lynch syndrome (LS) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS. Since then substantial new information has become available necessitating an update of the guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meetings. The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. The guidelines described in this paper may be helpful for the appropriate management of families with LS. Prospective controlled studies should be undertaken to improve further the care of these families.

Subfields: Epidemiology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/deff2f0f420d1f4082cf8bc942daf65b9fd4db86

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

Citations in the corpus

ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. (2015, background): “As screening will be of limited efficacy in gynaecological cancers (endometrial and ovarian), once the family is completed, particularly by age 35–40 years, careful consideration must be given to the option of prophylactic hysterectomy and bilateral salpingo-oophorectomy [30].”
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015, background): “As screening will be of limited efficacy in gynaecological cancers (endometrial and ovarian), once the family is completed, particularly by age 35Y40 years, careful consideration must be given to the option of prophylactic hysterectomy and bilateral salpingo-oophorectomy.(30) In women with LS, the f”